Skip to main content

Infections and the Kidney

  • Chapter
  • First Online:
Management of Kidney Diseases

Abstract

Infections of the kidney and urinary tract are a common cause of morbidity, and sometimes mortality, especially in young women. The responsible pathogens include bacteria, viruses, protozoa, parasites, and fungi. The clinical nature of the infection can be different in the immunosuppressed, in the setting of kidney transplantation, and in other conditions, including vasculitis, glomerulopathy and cancer. Some infections can lead to systemic immune activation, which can in turn lead to kidney disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Ndulue C, Jisike-Onuigbo N, Anyanor A, Ozuemba B, Osakwe A, Oguejiofor N, et al. SAT-459 purple urine bag syndrome in a Nigerian with gastrointestinal bleeding. Kidney Int Rep. 2020;5(3):S191–2.

    Google Scholar 

  2. Godaly G, Ambite I, Svanborg C. Innate immunity and genetic determinants of urinary tract infection susceptibility. Curr Opin Infect Dis. 2015;28:88–96.

    CAS  PubMed  Google Scholar 

  3. Medina M, Castillo-Pino E. An introduction to the epidemiology and burden of urinary tract infections. Ther Adv Urol. 2019;11:3–7.

    Google Scholar 

  4. Tan CW, Chlebicki MP. Urinary tract infections in adults. Singap Med J. 2016;57(9):485–90.

    Google Scholar 

  5. Tandogdu Z, Wagenlehner FM. Global epidemiology of urinary tract infections. Curr Opin Infect Dis. 2016;29:73–9.

    PubMed  Google Scholar 

  6. NICE Guideline: urinary tract infection (lower): antimicrobial prescribing. www.nice.org.uk/guidance/ng109. Accessed 20 Apr 2020.

  7. EAU Guidelines. Edn. Presented at the EAU annual congress Barcelona 2019. isbn:978-94-92671-04-2.

    Google Scholar 

  8. Smelov V, Naber K, Bjerklund Johansen KE. Improved classification of urinary tract infection: future considerations. Eur Urol Suppl. 2016;5:71–80.

    Google Scholar 

  9. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):e103–20.

    PubMed  Google Scholar 

  10. Rubin RH, Shapiro ED, Andriole VT, Davis RJ, Stamm WE. Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis. 1992;15(suppl 1):S216–27.

    PubMed  Google Scholar 

  11. Anger J, Lee U, Ackerman AL, Chou R, Chughtai B, Clemens JQ, et al. Recurrent uncomplicated urinary tract infections in women: AUA/CUA/SUFU guideline. J Urol. 2019;202:282–9.

    PubMed  Google Scholar 

  12. NICE Guidance—Complicated urinary tract infections: ceftolozane/tazobactam. BJU Int. 2018;121:825–834.

    Google Scholar 

  13. NICE guideline: urinary tract infection (recurrent): antimicrobial prescribing. www.nice.org.uk/guidance/ng112. Accessed 20 Apr 2020.

  14. Kulchavenya E. Best practice in the diagnosis and management of urogenital tuberculosis. Ther Adv Urol. 2013;5:143–51.

    PubMed  PubMed Central  Google Scholar 

  15. Pang Y, Shang Y, Lu J, Liang Q, Dong L, Li Y, et al. GeneXpert MTB/RIF assay in the diagnosis of urinary tuberculosis from urine specimens. Sci Rep. 2017;7:6181. https://doi.org/10.1038/s41598-017-06517-0.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Cek M, Lenk S, Naber KG, Bishop MC, Johansen TEB, Botto H, et al. EAU guidelines for the management of genitourinary tuberculosis. Eur Urol. 2005;48:353–62.

    PubMed  Google Scholar 

  17. Yang C-W. Leptospirosis renal disease: emerging culprit of chronic kidney disease unknown etiology. Nephron. 2018;138:129–36.

    PubMed  Google Scholar 

  18. Qiang XH, Yu TO, Li YN, Zhou LX. Prognosis risk of urosepsis in critical care medicine: a prospective observational study. Biomed Res Int. 2016;2016:9028924, 5 pages. https://doi.org/10.1155/2016/9028924.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Neild GH, Thomson G, Nitsch D, et al. Renal outcome in adults with renal insufficiency and irregular asymmetrical kidneys. BMC Nephrol. 2004;5:12.

    PubMed  PubMed Central  Google Scholar 

  20. Global tuberculosis report 2021. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.

    Google Scholar 

  21. World Health Organization. Global tuberculosis report 2019. https://www.who.int/tb/publications/global_report/en/. Accessed 20 Apr 2020.

  22. Gonzalez OY, Teeter LD, Thanh BT, Musser JM, Graviss EA. Extrathoracic tuberculosis lymphadenitis in adult HIV seronegative patients: a population-based analysis in Houston, Texas, USA. Int J Tuberc Lung Dis. 2003;7:987–93.

    CAS  PubMed  Google Scholar 

  23. Daher EF, Silva Junior GB, Guardao Barros EJ. Review: renal tuberculosis in the modern era. Am J Trop Med Hyg. 2013;88(1):54–64.

    CAS  PubMed  Google Scholar 

  24. Mallinson WJW, Fuller RW, Levison DA, et al. Diffuse interstitial renal tuberculosis. An unusual cause of renal failure. QJM. 1981;198:137–48.

    Google Scholar 

  25. Oliveira B, Jayawardene S, Shah S. Single centre experience of granulomatous interstitial nephropathy; time for a new approach? Clin Kidney J. 2017;10:249–54.

    PubMed  PubMed Central  Google Scholar 

  26. Eastwood JB, Zaidi M, Maxwell JD, et al. Tuberculosis as primary renal diagnosis in end-stage uremia. J Nephrol. 1994;7:290–3.

    Google Scholar 

  27. Global leprosy update, 2016: accelerating reduction of disease burden. WHO Weekly Epidemiological Record. 2017;92(35):501–520.

    Google Scholar 

  28. Nakayama EE, Ura S, Fleury RN, Soares V. Renal lesions in leprosy: a retrospective study of 199 autopsies. Am J Kidney Dis. 2001;38(1):26–30.

    CAS  PubMed  Google Scholar 

  29. Silva Junior GB, Daher EF, Pires Neto RJ, et al. Leprosy nephropathy: a review of clinical and histopathological features. Rev Inst Med Trop Sao Paulo. 2015;57:15–20.

    PubMed  Google Scholar 

  30. Torgerson PR, Hagan JE, Costa F, Calcagno J, Kane M, Martinez-Silveira MS, et al. Global burden of leptospirosis: estimated in terms of disability adjusted life years. PLoS Negl Trop Dis. 2015;9:e0004122.

    PubMed  PubMed Central  Google Scholar 

  31. Herath NJ, Kularatne SA, Weerakoon KG, Wazil A, Subasinghe N, Ratnatunga NV. Long term outcome of acute kidney injury due to leptospirosis? A longitudinal study in Sri Lanka. BMC Res Notes. 2014;7:398.

    PubMed  PubMed Central  Google Scholar 

  32. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl. 2012;2:139–274.

    Google Scholar 

  33. Prasad N, Patel MR. Infection-induced kidney diseases. Front Med. 2018;5:327. https://doi.org/10.3389/fmed.2018.00327.

    Article  Google Scholar 

  34. Schiffl H. Renal recovery from acute tubular necrosis requiring renal replacement therapy: a prospective study in critically ill patients. Nephrol Dial Transplant. 2006;21:1248–52. https://doi.org/10.1093/ndt/gfk069.

    Article  PubMed  Google Scholar 

  35. Lopes JA, Jorge S, Resina C, Santos C, Pereira A, Neves J, et al. Acute kidney injury in patients with sepsis: a contemporary analysis. Int J Infect Dis. 2009;13:176–81.

    PubMed  Google Scholar 

  36. Hoste EA, Bagshaw SM, Bellomo R, Cely CM, Colman R, Cruz DN, et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med. 2015;41:1411–23.

    PubMed  Google Scholar 

  37. Naughton CA. Drug-induced nephrotoxicity. Am Fam Physician. 2008;78(6):743–50.

    PubMed  Google Scholar 

  38. Awdishu L, Mehta RL. The 6R’s of drug induced nephrotoxicity. BMC Nephrol. 2017;18:124. https://doi.org/10.1186/s12882-017-0536-3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Lizarraga KJ, Nayer A. Dengue-associated kidney disease. J Nephropathol. 2014;3(2):57–62.

    PubMed  Google Scholar 

  40. Nasim A, Anis S, Baqi S, Akhtar SF, Baig-Ansari N. Clinical presentation and outcome of dengue viral infection in live-related renal transplant recipients in Karachi, Pakistan. Transplant Infect Dis. 2013;5(15):516–25.

    Google Scholar 

  41. Jessie K, Fong MY, Devi S, Lam SK, Wong KT. Localization of dengue virus in naturally infected human tissues, by immunohistochemistry and in situ hybridization. J Infect Dis. 2004;189(8):1411–8.

    PubMed  Google Scholar 

  42. Méndez A, González G. [Dengue haemorrhagic fever in children: ten years of clinical experience]. Biomedica. 2003;23(2):180–193.

    Google Scholar 

  43. Jonsson CB, Figueiredo LTM, Vapalahti O. A global perspective on hantavirus ecology, epidemiology, and disease. Clin Microbiol Rev. 2010;23(2):412–41.

    CAS  PubMed  PubMed Central  Google Scholar 

  44. Krautkrämer E, Grouls S, Stein N, Reiser J, Zeier M. Pathogenic old world hantaviruses infect renal glomerular and tubular cells and induce disassembling of cell-to-cell contacts. J Virol. 2011;85(19):9811–23.

    PubMed  PubMed Central  Google Scholar 

  45. Ferluga D, Vizjak A. Hantavirus nephropathy. JASN. 2008;19(9):1653–8.

    CAS  PubMed  Google Scholar 

  46. Miettinen MH, Mäkelä SM, Ala-Houhala IO, Huhtala HSA, Kööbi T, Vaheri AI, et al. Ten-year prognosis of Puumala hantavirus-induced acute interstitial nephritis. Kidney Int. 2006;69(11):2043–8.

    CAS  PubMed  Google Scholar 

  47. Gamage CD, Sarathkumara YD. Chronic kidney disease of uncertain etiology in Sri Lanka: are leptospirosis and Hantaviral infection likely causes? Med Hypotheses. 2016;91:16–9.

    PubMed  Google Scholar 

  48. Prasad N, Novak JE, Patel MR. Kidney diseases associated with parvovirus B19, Hanta, Ebola, and dengue virus infection: a brief review. Adv Chronic Kidney Dis. 2019;26(3):207–19.

    PubMed  Google Scholar 

  49. Baseler L, Chertow DS, Johnson KM, Feldmann H, Morens DM. The pathogenesis of Ebola virus disease. Annu Rev Pathol. 2017;12:387–418.

    CAS  PubMed  Google Scholar 

  50. Uyeki TM, Mehta AK, Davey RT, Liddell AM, Wolf T, Vetter P, et al. Clinical management of Ebola virus disease in the United States and Europe. N Engl J Med. 2016;374(7):636–46.

    CAS  PubMed  PubMed Central  Google Scholar 

  51. Zolnourian ZR, Curran MD, Rima BK, Coyle PV, O’Neill HJ, Middleton D. Parvovirus B19 in kidney transplant patients. Transplantation. 2000;69(10):2198–202.

    CAS  PubMed  Google Scholar 

  52. Waldman M, Kopp JB. Parvovirus B19 and the kidney. Clin J Am Soc Nephrol. 2007;2(Suppl 1):S47–56.

    CAS  PubMed  Google Scholar 

  53. Wierenga KJ, Pattison JR, Brink N, Griffiths M, Miller M, Shah DJ, et al. Glomerulonephritis after human parvovirus infection in homozygous sickle-cell disease. Lancet. 1995;346(8973):475–6.

    CAS  PubMed  Google Scholar 

  54. Leiri N, Hotta O, Taguma Y. Characteristics of acute glomerulonephritis associated with human parvovirus B19 infection. Clin Nephrol. 2005;64(4):249–57.

    Google Scholar 

  55. Liefeldt L, Buhl M, Schweickert B, Engelmann E, Sezer O, Laschinski P, et al. Eradication of parvovirus B19 infection after renal transplantation requires reduction of immunosuppression and high-dose immunoglobulin therapy. Nephrol Dial Transplant. 2002;17(10):1840–2.

    CAS  PubMed  Google Scholar 

  56. Hirsch HH, Knowles W, Dickenmann M, Passweg J, Klimkait T, Mihatsch MJ, et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med. 2002;347(7):488–96.

    PubMed  Google Scholar 

  57. Randhawa PS, Finkelstein S, Scantlebury V, Shapiro R, Vivas C, Jordan M, et al. Human polyoma virus-associated interstitial nephritis in the allograft kidney. Transplantation. 1999;67(1):103–9.

    CAS  PubMed  Google Scholar 

  58. Hirsch HH, Brennan DC, Drachenberg CB, Ginevri F, Gordon J, Limaye AP, et al. Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation. 2005;79(10):1277–86.

    PubMed  Google Scholar 

  59. Drachenberg CB, Beskow CO, Papadimitriou JC, Cangro CB, Rocca M, Klassen DK, et al. Human polyoma virus infected cells (PoVIC): incidence in renal biopsies (BX), urine cytology and correlation with clinical presentation. Transplantation. 1999;67(7):S217.

    Google Scholar 

  60. Hirsch HH. Human polyomavirus and papillomavirus infection and disease posttransplant. In: Transplant infections. Springer; 2016. p. 631–652.

    Google Scholar 

  61. Nankivell BJ, Renthawa J, Jeoffreys N, Kable K, O’Connell PJ, Chapman JR, et al. Clinical utility of urinary cytology to detect BK viral nephropathy. Transplantation. 2015;99(8):1715–22.

    CAS  PubMed  Google Scholar 

  62. Drachenberg CB, Papadimitriou JC, Chaudhry MR, Ugarte R, Mavanur M, Thomas B, et al. Histological evolution of BK virus–associated nephropathy: importance of integrating clinical and pathological findings. Am J Transplant. 2017;17(8):2078–91.

    CAS  PubMed  Google Scholar 

  63. Nickeleit V, Singh HK, Randhawa P, Drachenberg CB, Bhatnagar R, Bracamonte E, et al. The Banff working group classification of definitive polyomavirus nephropathy: morphologic definitions and clinical correlations. J Am Soc Nephrol. 2018;29(2):680–93.

    PubMed  Google Scholar 

  64. Sawinski D, Goral S. BK virus infection: an update on diagnosis and treatment. Nephrol Dial Transplant. 2015;30(2):209–17.

    CAS  PubMed  Google Scholar 

  65. Hirsch HH, Randhawa P, AST Infectious Diseases Community of Practice. BK polyomavirus in solid organ transplantation. Am J Transplant. 2013r;13(Suppl 4):179–88.

    CAS  PubMed  Google Scholar 

  66. Cummins NW, Sohail MR. Cytomegalovirus, BK, and other viral infections of the kidney. In: Core concepts in parenchymal kidney disease. Springer; 2014. p. 229–240.

    Google Scholar 

  67. Helanterä I, Koskinen P, Finne P, Loginov R, Kyllönen L, Salmela K, et al. Persistent cytomegalovirus infection in kidney allografts is associated with inferior graft function and survival. Transpl Int. 2006;19(11):893–900.

    PubMed  Google Scholar 

  68. Agrawal V, Gupta RK, Jain M, Prasad N, Sharma RK. Polyomavirus nephropathy and cytomegalovirus nephritis in renal allograft recipients. Indian J Pathol Microbiol. 2010;53(4):672–5.

    PubMed  Google Scholar 

  69. Posadas Salas MA, Thompson J, Kadian M, Ngo T, Bruner E, Self S. Cytomegalovirus renal infection: rare manifestation of a common post-transplant viral infection-a case series. Transpl Infect Dis. 2019;21(6):e13169.

    PubMed  Google Scholar 

  70. Fogo A. Cytomegalovirus infection. Am J Kidney Dis. 2000;36(2):E7–8.

    CAS  PubMed  Google Scholar 

  71. Ferreira AC, Navarro D. Cytomegalovirus nephropathy in the transplant patient. Nephrol Dial Transplant. 2021;36:777–8. https://doi.org/10.1093/ndt/gfz194.

    Article  CAS  PubMed  Google Scholar 

  72. Kole AK, Roy R, Kole DC. An observational study of complications in chickenpox with special reference to unusual complications in an apex infectious disease hospital, Kolkata, India. J Postgrad Med. 2013;59(2):93–7.

    CAS  PubMed  Google Scholar 

  73. Os I, Ström EH, Stenehjem A, Gudmundsdottir H, Langberg H, Draganov B, et al. Varicella infection in a renal transplant recipient associated with abdominal pain, hepatitis, and glomerulonephritis. Scand J Urol Nephrol. 2001;35(4):330–3.

    CAS  PubMed  Google Scholar 

  74. Zaki S, Bhongade S, Shanbag P. Acute glomerulonephritis following varicella infection. Indian J Nephrol. 2012;22(1):64. https://doi.org/10.4103/0971-4065.83753.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Condom P, Mansuy J-M, Decramer S, Izopet J, Mengelle C. Atypical hemolytic uremic syndrome triggered by varicella infection. ID Cases. 2017;9:89–90.

    PubMed  PubMed Central  Google Scholar 

  76. Bazerbachi F, Haffar S, Garg SK, Lake JR. Extra-hepatic manifestations associated with hepatitis E virus infection: a comprehensive review of the literature. Gastroenterol Rep (Oxf). 2016;4(1):1–15.

    PubMed  Google Scholar 

  77. Pischke S, Hartl J, Pas SD, Lohse AW, Jacobs BC, Van der Eijk AA. Hepatitis E virus: infection beyond the liver? J Hepatol. 2017;66(5):1082–95.

    CAS  PubMed  Google Scholar 

  78. Agrawal P, Kumar V, Kumar A, Sachdeva MUS, Malhotra P, Nada R. Monoclonal Gammopathy of renal significance triggered by viral E hepatitis. Indian J Nephrol. 2019;29(1):50–2.

    CAS  PubMed  PubMed Central  Google Scholar 

  79. Kamar N, Rostaing L, Izopet J. Hepatitis E virus infection in immunosuppressed patients: natural history and therapy. In: Seminars in liver disease. New York: Thieme Medical Publishers; 2013. p. 62–70.

    Google Scholar 

  80. Andrievskaya M, Lenhart A, Uduman J. Emerging threat: changing epidemiology of hepatitis A and acute kidney injury. Adv Chronic Kidney Dis. 2019;26(3):171–8.

    PubMed  Google Scholar 

  81. Fan P-C, Chen Y-C, Tian Y-C, Chang C-H, Fang J-T, Yang C-W. Acute renal failure associated with acute non-fulminant hepatitis A: a case report and review of literature. Ren Fail. 2009;31(8):756–64.

    CAS  PubMed  Google Scholar 

  82. Bhimma R, Coovadia HM. Hepatitis B virus-associated nephropathy. Am J Nephrol. 2004;24(2):198–211.

    CAS  PubMed  Google Scholar 

  83. Kamimura H, Setsu T, Kimura N, Yokoo T, Sakamaki A, Kamimura K, et al. Renal impairment in chronic hepatitis B: a review. Diseases. 2018;6(2):52. https://doi.org/10.3390/diseases6020052.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Li D, Gao G, Jiang H, Tang Z, Yu Y, Zang G. Hepatitis B virus-associated glomerulonephritis in HBsAg serological-negative patients. Eur J Gastroenterol Hepatol. 2015;27(1):65–9.

    PubMed  Google Scholar 

  85. Lai K. Hepatitis-related renal disease. Futur Virol. 2011;6:1361–76.

    Google Scholar 

  86. Pipili C, Papatheodoridis G, Cholongitas E. Treatment of hepatitis B in patients with chronic kidney disease. Kidney Int. 2013;84:880–5.

    CAS  PubMed  Google Scholar 

  87. Gill K, Ghazinian H, Manch R, Gish R. Hepatitis C virus as a systemic disease: reaching beyond the liver. Hepatol Int. 2016;3(10):415–23.

    Google Scholar 

  88. Meyers CM, Seeff LB, Stehman-Breen CO, Hoofnagle JH. Hepatitis C and renal disease: an update 1. Am J Kidney Dis. 2003;42(4):631–57.

    PubMed  Google Scholar 

  89. Kidney Disease: Improving Global Outcomes HCV Work Group. KDIGO 2018 clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl. 2018;8(3):91–165.

    Google Scholar 

  90. Jotwani V, Atta MG, Estrella MM. Kidney disease in HIV: moving beyond HIV-associated nephropathy. JASN. 2017;28(11):3142–54.

    CAS  PubMed  PubMed Central  Google Scholar 

  91. Swanepoel CR, Atta MG, D’Agati VD, Estrella MM, Fogo AB, Naicker S, et al. Kidney disease in the setting of HIV infection: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int. 2018;93(3):545–59.

    PubMed  PubMed Central  Google Scholar 

  92. Fabian J, Naicker S. HIV and kidney disease in sub-Saharan Africa. Nat Rev Nephrol. 2009;5(10):591–8. https://doi.org/10.1038/nrneph.2009.141.

    Article  PubMed  Google Scholar 

  93. Kasembeli AN, Duarte R, Ramsay M, Mosiane P, Dickens C, Dix-Peek T, et al. APOL1 risk variants are strongly associated with HIV-associated nephropathy in black South Africans. JASN. 2015;26(11):2882–90.

    CAS  PubMed  PubMed Central  Google Scholar 

  94. Dummer PD, Limou S, Rosenberg AZ, Heymann J, Nelson G, Winkler CA, et al. APOL1 kidney disease risk variants: an evolving landscape. Semin Nephrol. 2015;35(3):222–36.

    CAS  PubMed  PubMed Central  Google Scholar 

  95. Kopp JB, Nelson GW, Sampath K, Johnson RC, Genovese G, An P, et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol. 2011;22(11):2129–37.

    CAS  PubMed  PubMed Central  Google Scholar 

  96. Nobakht E, Cohen SD, Rosenberg AZ, Kimmel PL. HIV-associated immune complex kidney disease. Nat Rev Nephrol. 2016;12(5):291–300.

    CAS  PubMed  Google Scholar 

  97. Cheng Y, Luo R, Wang K, et al. Kidney disease is associated with in-hospital death of COVID-19 patients. Kidney Int. 2020;97:829–38. https://doi.org/10.1016/kint.2020.03.005.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Chen YT, Shao SC, Hsu CK, et al. Incidence of acute kidney injury in COVID-19 infection: a systematic review and metanalysis. Crit Care. 2020;24:346. https://doi.org/10.1186/s13054-020-03009-y.

    Article  PubMed  PubMed Central  Google Scholar 

  99. Ali H, Daoud A, Mohamed MM, Salim SA, Yessayan L, Baharani J, et al. Survival rate in acute kidney injury superimposed COVID-19 patients: a systematic review and meta-analysis. Ren Fail. 2020;42:393–7. https://doi.org/10.1080/0886022x2020.17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Batlle D, Soler MJ, Sparks MA, Hiremath S, South AM, Welling PA, et al., on behalf of the COVID-19 and ACE2 in Cardiovascular, Lung, and Kidney Working Group. Acute kidney injury in COVID-19: emerging evidence of a distinct pathophysiology. JASN. 2020;31:1380–1383. https://doi.org/10.1681/ASN.2020040419.

  101. Kudose S, Batal I, Santoriello D, Xu K, Barasch J, Peleg Y, et al. Kidney biopsy findings in patients with COVID-19. JASN. 2020;31(9):2158–67. https://doi.org/10.1681/ASN.2020050744.

    Article  PubMed  PubMed Central  Google Scholar 

  102. Fisher M, Yunes M, Mokrzycki MH, et al. Chronic hemodialysis patients hospitalized with COVID-19—short-term outcomes in Bronx, New York. Kidney360. 2020;1(8):755–62. https://doi.org/10.34067/KID.0003672020.

    Article  PubMed  PubMed Central  Google Scholar 

  103. Akalin E, Azzi Y, Bartash R, et al. Covid-19 and kidney transplantation. N Engl J Med. 2020;382:2475–7. https://doi.org/10.1056/NEJMc2011117.

    Article  PubMed  Google Scholar 

  104. https://www.who.int/malaria/en/. Accessed 30 Apr 2020.

  105. World malaria report 2021. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.

    Google Scholar 

  106. Global distribution of Malaria in 2018—CDC ‘Heat’ Map. https://www.cdc.gov/malaria/travellers/country_table/a.html

  107. Barsoum RS. Malarial acute renal failure. J Am Soc Nephrol. 2000;11:2147–54.

    PubMed  Google Scholar 

  108. Das BS. Renal failure in malaria. J Vector Borne Dis. 2008;45:83–97.

    CAS  PubMed  Google Scholar 

  109. Manan JA, Ali H, Lal M. Acute renal failure associated with malaria. J Ayub Med Coll Abbottabad. 2006;4:47–52.

    Google Scholar 

  110. Barsoum RS. Malarial nephropathies. Nephrol Dial Transplant. 1998;13:1588–97.

    CAS  PubMed  Google Scholar 

  111. Kute VB, Trivedi HL, Vanikar AV, Shah PR, Gumber MR, Patel HV, et al. Plasmodium vivax malaria–associated acute kidney injury, India, 2010–2011. Emerg Infect Dis. 2012;18:842–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  112. Naqvi R. Plasmodium vivax causing acute kidney injury: a foe less addressed. Pak J Med Sci. 2015;31:1472–5.

    PubMed  PubMed Central  Google Scholar 

  113. Bircan Z, Kervancioglu M, Soran M, Gonlusen G, Tuncer I. Two cases of nephrotic syndrome and tertian malaria in South-Eastern Anatolia. Pediatr Nephrol. 1997;11(1):78–9.

    CAS  PubMed  Google Scholar 

  114. da Silva Junior GB, Pinto JR, Barros EJG, Geysa Farias GMN, De Francesco DE. Kidney involvement in malaria: an update. Rev Inst Med Trop São Paulo. 2017;59:e53. https://doi.org/10.1590/S1678-9946201759053.

    Article  PubMed  Google Scholar 

  115. Poti KE, Sullivan DJ, Dondorp AM, Woodrow CJ. HRP2: transforming malaria diagnosis, but with caveats. Trends Parasitol. 2020;36(2):112–26. https://doi.org/10.1016/j.pt.2019.12.004.

    Article  PubMed  Google Scholar 

  116. Plucinski MM, Candrinho B, Dimene M, Colborn J, Lu A, Nace D, et al. Assessing performance of HRP2 antigen detection for malaria diagnosis in Mozambique. J Clin Microbiol. 2019;57(9):e00875–919. https://doi.org/10.1128/JCM.00875-19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  117. WHO Malaria Publications. Management of severe malaria. In: A practical handbook. 3rd ed. 2012. isbn:978-92-4-154852-6. https://www.who.int/malaria/publications/atoz/9789241548526/en/

  118. Ismail SA, Kamal W, Salem HK. Schistosoma prevalence world-wide. In: Schistosomiasis. 2016. isbn:978-1-944685-64-5. http://www.smgebooks.com/schistosomiasis/index.php#

  119. World Health Organization. https://www.who.int/schistosomiasis/epidemiology/table3/en/. Accessed 2 May 2020.

  120. CDC. www.cdc.gov/parasites/schistosomiasis. Accessed 2 May 2020.

  121. da Silva Junior GB, Duarte DB, Barros EJ, De Francesco DE. Schistosomiasis-associated kidney disease: a review. Asian Pac J Trop Dis. 2013;3(1):79–84.

    Google Scholar 

  122. Barsoum RS. Schistosomal glomerulopathies. Kidney Int. 1993;44:1–12.

    CAS  PubMed  Google Scholar 

  123. Seck SM, Sarr ML, Dial MC, Ka EF. Schistosoma hematobium-associated glomerulopathy. Indian J Nephrol. 2011;21(3):201–3. https://doi.org/10.4103/0971-4065.78076.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  124. Barsoum RS, Esmat G, El-Baz T. Human schistosomiasis: clinical perspective. J Adv Res. 2013;4(5):433–44.

    PubMed  PubMed Central  Google Scholar 

  125. Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan WC. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis. 1992;15:414–21. https://doi.org/10.1093/clind/15.3.414.

    Article  CAS  PubMed  Google Scholar 

  126. Singh N. Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis. 2001;33:1692–6. https://doi.org/10.1086/323895.

    Article  CAS  PubMed  Google Scholar 

  127. Badiee P, Hashemizadeh Z. Opportunistic invasive fungal infections: diagnosis & clinical management. Indian J Med Res. 2014;139:195.

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Saraladevi Naicker .

Editor information

Editors and Affiliations

Questions

Questions

  1. 1.

    A 55 year old man presented to the emergency room with fever, non-productive cough, anosmia, muscle aches and fatigue for one day and sore throat for 3 days. He had been to his local pub 5 days previously. His temperature was 38.3 °C, BP 124/76, respiratory rate 28/min and oxygen saturation 88%. Chest radiograph was suggestive of bilateral lower lobe interstitial pneumonitis. Laboratory results revealed haemoglobin 13.3 g/dL; white cell count 4.1 × 109/L; lymphocyte count 1.3 × 109/L; blood glucose 12.2 mmol/L; serum creatinine 98 μmol/L; CRP 185 mg/L. Three days after admission he was breathless and transferred to ITU, his creatinine increased to 210 μmol/L.

    What is the most likely cause of his illness?

    1. A.

      COVID-19

    2. B.

      Cytomegalovirus infection

    3. C.

      Staphylococcus infection

    4. D.

      Pneumococcus infection

    5. E.

      Malaria

    Answer: A

    A nasal swab PCR confirmed the diagnosis of COVID-19. He was admitted to the intensive care unit and commenced on intravenous fluids, high flow oxygen via a nasal cannula, enoxaparin 20 mg subcutaneously, dexamethasone 6 mg daily intravenously and insulin adjusted according to glucometer readings. He was transferred out of ICU after 5 days and continued to improve in hospital.

  2. 2.

    A 30 year old black woman, recipient of a deceased donor kidney transplant 3 months previously, was noted to have a decline in her baseline kidney function at a clinic visit. She had received antithymocyte globulin, high dose steroid induction therapy and was being maintained on tacrolimus, mycophenolate mofetil (MMF) and prednisolone. She had been noted to be CMV IgG positive while on dialysis. Her BP was130/60 mmHg, pulse 78/min and temperature 39 °C. Laboratory tests: haemoglobin 11.8 g/dL; WCC 3.1 × 109/L; platelet count 130,000; serum creatinine 180 μmol/L from a previous baseline of 110 μmol/L. Urine examination revealed 50 red cells/HPF and proteinuria of 0.5 g/day. Tacrolimus levels were between 5 and 15 ng/mL. She underwent a kidney biopsy.

    Histology of the allograft biopsy showed a peritubular mononuclear interstitial infiltrate; some tubular cells had intranuclear inclusions.

    What is the most likely diagnosis?

    1. A.

      Acute cellular rejection

    2. B.

      Acute antibody mediated rejection

    3. C.

      BK virus infection

    4. D.

      Cytomegalovirus infection

    5. E.

      Tacrolimus toxicity

    Answer: D

    CMV viral load was 15,000 copies/mL. She was treated with intravenous ganciclovir 5 mg/kg every 12 h for 14 days, and thereafter maintained on valganciclovir 900 mg daily for 30 days. MMF was discontinued, tacrolimus dose was optimized according to blood levels, and she continued with low dose prednisolone. Her serum creatinine stabilized at 125 μmol/L.

  3. 3.

    An 18-year old boy, recipient of a second (deceased donor) kidney transplant was noted to have an asymptomatic rise in his serum creatinine during a routine clinic visit 12 months after transplantation. He had received antithymocyte globulin, high dose steroid induction therapy and was being maintained on tacrolimus, mycophenolate mofetil (MMF) and prednisolone. He had been noted to be CMV IgG positive previously. He was noted to have haemoglobin 12.8 g/dL; WCC 5.1 × 109/L; platelet count 230,000; serum creatinine 220 μmol/L from a previous baseline of 120 μmol/L. Urine cytology showed epithelial cells with viral inclusions ‘decoy cells’, Allograft biopsy showed mononuclear interstitial inflammation, and some degree of tubulitis with basophilic changes of the tubular epithelium.

    What is the most likely diagnosis?

    1. A.

      Acute cellular rejection

    2. B.

      Acute antibody mediated rejection

    3. C.

      BK virus infection

    4. D.

      Cytomegalovirus infection

    5. E.

      Tacrolimus toxicity

    Answer: C

    He had a urine BK load of 117 copies/mL and a serum BK viral load of 105 copies/mL. His MMF dose was halved, and tacrolimus trough levels lowered and he was treated with leflunomide 100 mg daily for 5 days and 40 mg daily thereafter until the virus was cleared. His kidney function gradually stabilized to around his baseline levels and surveillance for BKV is carried out on a monthly basis.

  4. 4.

    A 45 year old black man was recently diagnosed with HIV infection and referred to a Renal Clinic with proteinuria and renal dysfunction. He had minimal ankle oedema, BP 126/82 and had 3 g proteinuria/day. His serum albumin was 25 g/L, serum cholesterol 4.1 mmol/L, serum creatinine 188 μmol/L, eGFR 42.1 mL/min/1.73 m2, CD4 count 180 cells/mL, viral load 125,000 copies/mL. He underwent a kidney biopsy.

    What is the most likely biopsy diagnosis?

    1. A.

      Crescentic glomerulonephritis

    2. B.

      Focal segmental glomerulonephritis

    3. C.

      Membranous glomerulonephritis

    4. D.

      Membranoproliferative glomerulonephritis

    5. E.

      Minimal change disease

    Answer: B

    His kidney biopsy showed typical HIV associated nephropathy, with glomerular collapse, microcystic tubular dilatation and interstitial inflammation. He was commenced on Losartan 50 mg daily, and Abacavir 300 mg BD, Lamuvidine (3TC) 150 mg daily and Dolutegravir 50 mg daily. Avoid fixed dose combinations if GFR < 50 mL/min, and tenofovir if possible. His APOL1 genotype was not available.

  5. 5.

    A 25 year old man was admitted to the emergency room with a fever of 39.1 °C, and dehydration. He had been on a beach vacation in Mozambique 2 weeks previously. He was noted to have tachycardia of 100/min, BP 96/60 and was pale and had a 2 cm splenomegaly. His haemoglobin was 10.1 g/dL; white cell count 4.1 × 109/L; platelets 92,000; serum bilirubin 35 mmol/L; blood urea 32 mmol/L; serum creatinine 220 μmol/L.

    What is the most likely cause of his acute kidney injury?

    1. A.

      Cytomegalovirus infection

    2. B.

      Epstein barr virus infection

    3. C.

      Malaria

    4. D.

      Pneumococcal infection

    5. E.

      Staphylococcus infection

    Answer: C

    A thin smear revealed the presence of tropozoites of P falciparum. He was commenced on intravenous fluids and therapy with artesunate 2.4 mg/kg intravenously immediately and 12 hourly for 24 h and thereafter switched to oral treatment with artemether-lumefantrine for 3 days. A blood smear at 72 h demonstrated that the parasitaemia had been eradicated and he made a a full recovery.

  6. 6.

    A 45 year old man, a visitor from Egypt, was hospitalized with abdominal distension. He had been an agricultural worker. He was noted to have hepatosplenomegly. Investigations showed dipstick proteinuria of 3+, and was measured to be 2.9 g/24 h; serum albumin 35 g/L; serum globulins 50 g/L; haemoglobin was 10.8 g/dL; white cell count 4.1 × 109/L; platelets 112,000; serum bilirubin 10 mmol/L; blood urea 5 mmol/L; serum creatinine 88 μmol/L. Ultrasound of the liver was suggestive of hepatic fibrosis, and was confirmed by fibroscan. A kidney biopsy showed membranoproliferative glomerulonephritis.

    What is the cause of the renal disease?

    1. A.

      Cytomegalovirus infection

    2. B.

      Hepatitis B infection

    3. C.

      HIV infection

    4. D.

      Malaria

    5. E.

      Schistosomiasis

    Answer: E

    A stool specimen showed the presence of schistosoma mansoni. He was treated with praziquantel and advised to avoid future schistosomal infection, and to return to his physician for review.

  7. 7.

    A 25 year old forest worker in the Democratic Republic of the Congo presented to the Emergency Department with 3 day history of headache, fever, shivering at night, muscle ache and joint pains. The headache was worst behind the eyes and he also mentioned shivering at night. His temperature was 40.0 °C with a BP of 100/60 and regular tachycardia of 120/min. By Day 4 he had developed a maculo-papular rash with patches of purpura. Haemoglobin 13.0 g/dL, WBC 4.0 × 109/L, platelets 80 × 109/L [normal: 150–400]. Creatinine 350 μmol/L with urea 40 mmol/L, eGFR 24 mL/min/1.73 m2. There was proteinuria 0.6 g/L and RBC 50–100/μL. Renal biopsy was not considered as it was felt that it would not influence treatment; furthermore it would add an unnecessary hazard for someone already at risk of bleeding.

    What is the most likely diagnosis?

    1. A.

      COVID 19 infection

    2. B.

      Dengue fever

    3. C.

      Ebola virus infection

    4. D.

      Malaria

    5. E.

      Tuberculosis infection

    Answer: B

    He was diagnosed with Dengue fever and managed with supportive treatment and scrupulous attention to clinical signs, pulse, blood pressure and urine output replacing fluid as necessary but avoiding overload. There is unfortunately no specific treatment for dengue virus and as yet no vaccine.

  8. 8.

    An 18 year-old female presented with history of fever for 2 weeks, and the passage of brown urine for 6 days, generalized body swelling for 5 days followed by reduced urine output and breathlessness for 2 days. She had a seizure episode a few hours before presentation. She had noted skin infections 3 weeks preceding the above symptoms. On presentation, she had impaired consciousness (GCS 8/15) but recovered within a few hours. She was pale, with bilateral pitting leg oedema temperature of 37.8 °C, respiratory rate 38 breaths/min, pulse 110 bpm and BP 160/110 mmHg. Urinalysis showed blood, protein, and microscopy revealed red cell casts. Her blood tests showed sodium: 122 mmol/L, potassium: 5.6 mmol/L, HCO3: 12.4 mmol/L, chloride: 84.4, iCa: 1.01, BUN: 63.3 mmol/L, creatinine: 884 μmol/L, haemoglobin: 8.3 g/dL, leukocytosis with neutrophila of 78%.

    What is the most likeley investigation which will help with diagnosis?

    1. A.

      ASO titre

    2. B.

      ANCA

    3. C.

      Hepatitis B serology

    4. D.

      Kidney biopsy

    5. E.

      Serum immunoglobulin

    Answer: A

    Her ESR was 125 mm/hr and qualitative ASO titre: elevated/positive

  9. 9.

    An 18 year-old female presented with history of fever for 2 weeks, red-brown coloured urine for 6 days, generalized body swelling for 5 days followed by reduced urine output and breathlessness for 2 days. She had a seizure episode a few hours before presentation. She had noted skin infections 3 weeks preceding the above symptoms. On presentation, she had impaired consciousness (GCS 8/15) but recovered within a few hours. She was pale, with bilateral pitting leg oedema temperature of 37.8 °C, respiratory rate 38 breaths/min, pulse 110 bpm and BP 160/110 mmHg. Urinalysis showed blood, protein, and microscopy revealed red cell casts. Her blood tests showed sodium: 122 mmol/L, potassium: 5.6 mmol/L, HCO3: 12.4 mmol/L, chloride: 84.4, iCa: 1.01, BUN: 63.3 mmol/L, creatinine: 884 μmol/L, haemoglobin: 8.3 g/dL, leukocytosis with neutrophila of 78%.

    What is the most likely diagnosis?

    1. A.

      Haemolytic uraemic syndrome

    2. B.

      IgA nephritis

    3. C.

      Lupus nephritis

    4. D.

      Post infectious glomerulonephritis

    5. E.

      Polyarteritis nodosa

    Answer: D

    Her ESR was 125 mm/hr and qualitative ASO titre: elevated/positive

  10. 10.

    A 42 year old rural drainage engineer, living in Sao Paulo state in southern Brazil, presented to the Dermatology clinic giving a history of intermittent skin rash sometimes associated with a change in pigmentation. He was found to have heavy proteinuria and referred to the nephrologist. In recent months he had been feeling more tired than usual. He had a pale complexion. There was mild oedema of the ankles. Temperature: 36.5 °C, Haemoglobin 100 g/L, sodium 140 mmol/L, Potassium 5.3 mmol/L, bicarbonate 22 mmol/L, creatinine 216 μmol/L, albumin 23 g/L. Urine protein amounted to 10.5 g/24 h. An MSU revealed neither cells nor blood or glucose; the urine was sterile on culture. A repeat of the investigations a week later gave similar results.

    What is the most likely diagnosis?

    1. A.

      Leptospirosis

    2. B.

      Systemic lupus erythematosus

    3. C.

      Nephropathy of tuberculoid leprosy

    4. D.

      Amyloidosis secondary to lepromatous leprosy

    5. E.

      Falciparum malaria

    Answer: D Amyloidosis secondary to lepromatous leprosy

A. Leptospirosis

Incorrect

Lack of fever, and no active urinary sediment

B. Systemic lupus erythematosus

Incorrect

No joint pain, no fever, no significant urinary sediment

C. Nephropathy of tuberculoid leprosy

Incorrect

Nephrotic syndrome not common in the tuberculoid form of leprosy

D. Amyloidosis secondary to lepromatous leprosy with nephrotic syndrome

Correct

Frequency of amyloidosis in leprosy types: lepromatous [36%], tuberculoid and borderline [5%]. The nephrotic syndrome is a consequence of the amyloidosis.

E. Falciparum malaria

Incorrect

No fever or other evidence of malaria

Test your learning and check your understanding of this book’s contents: use the “Springer Nature Flashcards” app to access questions using https://sn.pub/cz9Cok. To use the app, please follow the instructions in Chap. 1.

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Naicker, S., Eastwood, J.B., Ashuntantang, G., Ulasi, I. (2023). Infections and the Kidney. In: Banerjee, D., Jha, V., Annear, N.M. (eds) Management of Kidney Diseases. Springer, Cham. https://doi.org/10.1007/978-3-031-09131-5_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-09131-5_14

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-09130-8

  • Online ISBN: 978-3-031-09131-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics